Revista Espanola de Quimioterapia

metrics 2024

Advancing Clinical Insights for Tomorrow's Therapies

Introduction

The Revista Espanola de Quimioterapia, published by the SOCIEDAD ESPANOLA QUIMIOTERAPIA, is a pivotal open-access journal that has been advancing the field of clinical microbiology and pharmacology since its inception in 1989. With an E-ISSN of 1988-9518, this journal caters to a diverse audience of researchers, healthcare professionals, and students, providing them with critical insights into the latest developments in medicinal chemistry and therapeutic strategies. Located in Madrid, Spain, the journal reflects the rigorous academic standards of its associated institutions, contributing significantly to the translation of research into clinical practice. Achieving a Q3 ranking in the fields of Medicine, Microbiology, and Pharmacology in 2023 attests to its growing influence and relevance in the scientific community, making it a vital resource for those engaged in the quest for innovative solutions to pressing healthcare challenges. The journal prides itself on its commitment to maintaining an open-access model since 2018, ensuring that vital research is freely accessible to foster greater knowledge sharing and collaboration within the global scientific community.

Metrics 2024

SCIMAGO Journal Rank0.40
Journal Impact Factor1.90
Journal Impact Factor (5 years)1.80
H-Index32
Journal IF Without Self1.90
Eigen Factor0.00
Normal Eigen Factor0.28
Influence0.39
Immediacy Index0.70
Cited Half Life4.20
Citing Half Life4.00
JCI0.44
Total Documents1750
WOS Total Citations1036
SCIMAGO Total Citations3736
SCIMAGO SELF Citations448
Scopus Journal Rank0.40
Cites / Document (2 Years)1.35
Cites / Document (3 Years)1.23
Cites / Document (4 Years)1.29

Metrics History

Rank 2024

Scopus

Microbiology (medical) in Medicine
Rank #89/140
Percentile 36.43
Quartile Q3
Pharmacology in Pharmacology, Toxicology and Pharmaceutics
Rank #213/313
Percentile 31.95
Quartile Q3

IF (Web Of Science)

MICROBIOLOGY
Rank 130/161
Percentile 19.60
Quartile Q4
PHARMACOLOGY & PHARMACY
Rank 231/354
Percentile 34.90
Quartile Q3

JCI (Web Of Science)

MICROBIOLOGY
Rank 129/161
Percentile 19.88
Quartile Q4
PHARMACOLOGY & PHARMACY
Rank 257/354
Percentile 27.40
Quartile Q3

Quartile History

Similar Journals

JOURNAL OF BIOMEDICAL SCIENCE

Innovating biomedicine: Where research meets accessibility.
Publisher: BMCISSN: 1021-7770Frequency: 1 issue/year

JOURNAL OF BIOMEDICAL SCIENCE, published by BMC, is a premier Open Access journal dedicated to the rapid dissemination of research in the fields of biomedical science, encompassing crucial areas such as biochemistry, cell biology, clinical biochemistry, and more. Since its inception in 1993, the journal has established itself as a leading publication, currently boasting a remarkable impact factor and quality as evidenced by its Q1 quartile rankings across multiple categories in 2023. With an impressive track record, including a Scopus ranking in the top percentiles across several disciplines, it serves as a vital resource for researchers, professionals, and students who are keen on advancing their knowledge in biomedicine. The journal operates under a fully Open Access model, ensuring that all published articles are freely available to the global research community, thus contributing to the broader dissemination and accessibility of scientific knowledge. Based in the United Kingdom, JOURNAL OF BIOMEDICAL SCIENCE is committed to fostering innovation and collaboration in research, appealing to those aiming to make impactful contributions to the biomedical sphere.

CLINICAL MICROBIOLOGY AND INFECTION

Pioneering Research in Infectious Diseases
Publisher: ELSEVIER SCI LTDISSN: 1198-743XFrequency: 12 issues/year

CLINICAL MICROBIOLOGY AND INFECTION is a leading journal published by Elsevier Science Ltd, dedicated to advancing the field of infectious diseases and clinical microbiology. With its ISSN 1198-743X and E-ISSN 1469-0691, this esteemed journal has maintained its influential presence since 1995, showcasing high-impact research that addresses critical issues in the diagnosis, treatment, and prevention of infections. Ranked in the Q1 quartile for Infectious Diseases, Medicine (miscellaneous), and Microbiology (medical) categories, and boasting impressive Scopus rankings of #12 and #7 respectively, it sits at the forefront of scientific inquiry in these disciplines. Although it is not an Open Access journal, it provides comprehensive access options for institutions and individuals, ensuring the dissemination of vital research findings. As the field of clinical microbiology continues to evolve, CLINICAL MICROBIOLOGY AND INFECTION remains an essential resource for researchers, clinicians, and students aiming to stay informed on the latest developments and breakthroughs in understanding infectious diseases.

Indonesian Journal of Pharmacy

Connecting global minds in the pursuit of pharmaceutical excellence.
Publisher: UNIV GADJAH MADA, FAC FARMASIISSN: 2338-9486Frequency: 4 issues/year

Indonesian Journal of Pharmacy (ISSN: 2338-9486; E-ISSN: 2338-9427), published by UNIV GADJAH MADA, FAC FARMASI, stands as a significant platform for disseminating pioneering research in the field of pharmacy and pharmacology. Since its transition to an Open Access format in 2011, the journal has enhanced its visibility and accessibility, catering to a global audience of researchers, practitioners, and students. With a commendable Q3 category ranking in Pharmaceutical Science, Pharmacology, and Pharmacy for 2023, along with its respectable Scopus ranks, it provides valuable insights and advancements in the pharmaceutical sciences, particularly relevant to the Indonesian context and beyond. The journal not only supports the academic community but also contributes to the enhancement of healthcare practices through rigorous peer-reviewed publications. By fostering knowledge exchange and collaboration, the Indonesian Journal of Pharmacy aims to play a pivotal role in advancing research and development in pharmacy-related disciplines.

New Microbiologica

Fostering innovation in the ever-evolving world of microbiological research.
Publisher: EDIZIONI INT SRLISSN: 1121-7138Frequency: 4 issues/year

New Microbiologica is a prominent academic journal published by EDIZIONI INT SRL, dedicated to advancing knowledge in the fields of Microbiology and Medicine. Since its inception in 1993, this journal has played a vital role in disseminating cutting-edge research, featuring articles that explore the intricate relationships between microorganisms and human health. With an H-index indicating a robust citation profile and a respectable 2023 Scopus Ranking placing it in the 32nd percentile for medicine microbiology, New Microbiologica resonates well within the academic community. Although not an Open Access journal, it is strategically positioned in Quartile 3 of both Medicine (miscellaneous) and Medical Microbiology categories, which reflects its importance to researchers and professionals seeking valuable insights in their fields. Published in Italy, the journal continues to provide a platform for impactful research through its commitment to high-quality publications, fostering collaboration and innovation among scientists and academics in the ever-evolving landscape of microbiological studies.

Microbial Drug Resistance

Elevating Research on the Frontlines of Drug Resistance
Publisher: MARY ANN LIEBERT, INCISSN: 1076-6294Frequency: 10 issues/year

Microbial Drug Resistance, published by MARY ANN LIEBERT, INC, is a pivotal journal that explores the critical intersection of microbiology and pharmacology with a keen focus on antibiotic resistance and related issues. Since its inception in 1995, this journal has established itself as a vital resource for researchers, healthcare professionals, and students, offering a platform for innovative studies that inform the global response to antimicrobial resistance. With a commendable position in the Category Quartiles, ranked Q2 in Medicine (miscellaneous) and Q2 in Pharmacology for 2023, it caters to a multidisciplinary audience by addressing the implications of microbial resistance within various medical contexts. Although currently non-Open Access, the journal allows subscribers and institutions to access high-quality, peer-reviewed research, directly impacting policy and practice in healthcare settings. Committed to advancing our understanding and combating the challenges posed by resistant microbes, Microbial Drug Resistance remains an essential publication in the fields of microbiology, immunology, and pharmacology.

International Journal of Antimicrobial Agents

Advancing the Fight Against Antimicrobial Resistance
Publisher: ELSEVIERISSN: 0924-8579Frequency: 12 issues/year

International Journal of Antimicrobial Agents, published by Elsevier, stands as a premier platform in the fields of Infectious Diseases, Microbiology, and Medical Pharmacology. With an impressive impact factor and ranked in the Q1 category across multiple medical disciplines in 2023, this journal is recognized for its contribution to advancing knowledge and understanding in the efficacy and safety of antimicrobial treatments. Its comprehensive scope from 1991 to 2024 allows for the publishing of original research, reviews, and commentary on pressing issues related to antimicrobial resistance, treatment strategies, and pharmacological innovations. With a strong emphasis on high-quality research as reflected in its Scopus rankings, the journal is an essential resource for researchers, clinicians, and students dedicated to improving patient outcomes in the face of evolving microbiological challenges. Engage with the latest findings and methodologies through this vital academic resource, available in print and online, from the heart of the Netherlands.

Current Infectious Disease Reports

Advancing the Frontiers of Infectious Disease Knowledge
Publisher: SPRINGERISSN: 1523-3847Frequency: 12 issues/year

Current Infectious Disease Reports, published by SPRINGER, is a leading journal dedicated to advancing knowledge in the field of infectious diseases. With an ISSN of 1523-3847 and an E-ISSN of 1534-3146, this peer-reviewed journal has established itself as a vital resource for researchers and healthcare professionals since its inception in 1999. The journal's impact in the academic community is underscored by its Q1 ranking in Infectious Diseases for 2023, placing it in the top quartile of influential journals in the field. Furthermore, it holds a respectable position at rank #95 out of 344 in the Scopus database, reflecting its substantial contribution to medicine and public health. While currently not an open access journal, it offers a wealth of articles covering the latest research, case studies, and reviews, making it an indispensable tool for those aiming to stay at the forefront of infectious disease science. As we navigate an era marked by emerging and re-emerging infectious threats, Current Infectious Disease Reports remains committed to providing high-quality, relevant research that supports evidence-based practice and informs future studies globally.

Mediterranean Journal of Infection Microbes and Antimicrobials

Exploring the intricate world of microbes and health.
Publisher: GALENOS PUBL HOUSEISSN: 2147-673XFrequency: 1 issue/year

Mediterranean Journal of Infection Microbes and Antimicrobials is a distinguished open-access journal published by GALENOS PUBL HOUSE, dedicated to advancing the understanding of infectious diseases and microbiology. Since its inception in 2011, this journal has been a vital resource for researchers, professionals, and students interested in the intricate world of microbes and their impacts on human health. With its ISSN 2147-673X, the journal has progressively gained visibility, although it currently holds a Q4 ranking in multiple categories including Immunology and Microbiology, and Infectious Diseases for the year 2023. The journal operates from its headquarters in Istanbul, Turkey, and features a rich array of articles that contribute to the field’s body of knowledge. As a platform enhancing the accessibility of research, it invites submissions from global contributors to foster collaboration and innovation in tackling microbial challenges.

INFECTIOUS DISEASES IN CLINICAL PRACTICE

Advancing knowledge in infectious disease management.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1056-9103Frequency: 6 issues/year

INFECTIOUS DISEASES IN CLINICAL PRACTICE, published by Lippincott Williams & Wilkins, is a crucial resource in the field of infectious diseases and microbiology. With an ISSN of 1056-9103 and an E-ISSN of 1536-9943, this journal has been a platform for scholarly communication since its inception in 1992, now spanning over two decades of continuous publication. The journal primarily focuses on the latest research developments, case studies, and clinical practices relevant to infectious diseases, making it an indispensable tool for researchers, healthcare professionals, and students alike. Although it is currently categorized in the Q4 quartile for both Infectious Diseases and Medical Microbiology, it continues to strive for excellence and relevance in a rapidly evolving field. By facilitating open access to impactful articles (note: Open Access not applicable), the journal aims to enhance global understanding and management of infectious diseases, ensuring that practitioners are well-equipped to confront contemporary challenges in this critical area of public health. Situated in the United States at TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103, INFECTIOUS DISEASES IN CLINICAL PRACTICE plays an essential role in fostering academic discourse and advancing clinical knowledge.

Infectious Disease Reports

Bridging gaps in understanding infectious diseases worldwide.
Publisher: MDPIISSN: Frequency: 6 issues/year

Infectious Disease Reports is a premier open-access journal published by MDPI, dedicated to advancing the field of infectious diseases. Since its inception in 2009, this journal has established itself as a significant platform for disseminating cutting-edge research, reviews, and case studies, critical for global health. With a commendable Q2 ranking in the category of Infectious Diseases and a Scopus rank of #140 out of 344, it is recognized for its impactful contributions to medical research, holding a 59th percentile in its field. The journal aims to provide comprehensive insights into various dimensions of infectious diseases, ranging from epidemiology to novel treatment modalities. As an open-access publication, Infectious Disease Reports ensures that its articles are freely available to a wide audience, fostering collaborative efforts among researchers, healthcare professionals, and students worldwide. With its ongoing commitment to excellence, the journal plays an essential role in shaping the future of infectious disease research.